BriaCell Therapeutics (BCTX) · BriaPro TILsRx
Later window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: first half of 2025
Human clinical studies are expected to be initiated in the first half of 2025.
· filed · SEC filing
After
Stated timing: first half of 2027
Human clinical studies are expected to be initiated in the first half of 2027, pending funding.
EX-99.2 · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/BCTX-briapro-tilsrx-2025-12-01, data as of Oct 14, 2026
https://www.orionbiotechai.com/changes/BCTX-briapro-tilsrx-2025-12-01
BriaCell Therapeutics (BCTX) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-K is a company’s annual report to the SEC, with audited financial statements.